Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96MP8
UPID:
KCTD7_HUMAN
Alternative names:
-
Alternative UPACC:
Q96MP8; A4D2M4; Q8IVR0
Background:
BTB/POZ domain-containing protein KCTD7 plays a crucial role in the control of cortical neuron excitability. This protein's involvement in neuronal activities underscores its significance in the central nervous system.
Therapeutic significance:
KCTD7 is linked to Epilepsy, progressive myoclonic 3, a severe neurological disorder characterized by myoclonic seizures and neurodegeneration. Understanding the role of KCTD7 could open doors to potential therapeutic strategies for this debilitating condition.